MaxCyte, Inc. (MXCT) Stock Price & Analysis
MaxCyte, Inc. (MXCT) closed at USD 1.3 on Thursday, October 15, 2026, up 4.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.25; the Oct 15, 2026 session ranged USD 1.26–1.31 on volume of 3,787,175 shares. Market capitalization is $134.17M, with a 52-week range of USD 0.64–1.81 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MXCT.md
Key facts (MXCT)
- Analysts: Buy (mean 2.17 on a 1–5 scale) (6 analysts), mean target USD 4.11 (range 2.43–5).
- Total return with dividends: 1Y -26.6% vs S&P 500 +18.1%; 5Y -88.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-10, EPS estimate USD -0.08, revenue estimate $7.5M.
Analysts (MXCT)
Consensus Buy (mean 2.17 on a 1–5 scale), 6 analysts; mean target USD 4.11 (low 2.43, high 5).
Total return (dividends reinvested) (MXCT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -26.6% | -88.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -26.6% | -34.7% |
| Volatility (annualized) | 69.8% | 64.9% |
| Max drawdown | -61.8% (Oct 2025→Mar 2026) | -94.7% (Nov 2021→Mar 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 1.3 |
|---|---|
| Change | ▲ 4.00% (up) |
| Previous Close | USD 1.25 |
| Open | USD 1.27 |
| Day Range | USD 1.26 – 1.31 |
| 52-Week Range | USD 0.64 – 1.81 |
| Volume | 3,787,175 shares |
| Market Cap | $134.17M |
| Exchange | NMS |
Technical Analysis (MXCT)
Nexqual's technical model rates MXCT "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.2 (neutral) |
| vs SMA50 | Above (USD 1.21) |
| MACD | -0.02 (negative) |
Analyst Ratings (MXCT)
Wall Street analysts rate MXCT "Buy" based on 6 analysts, with a mean price target of USD 4.11 (range USD 2.43–5), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 4.11 |
| High Target | USD 5 |
| Low Target | USD 2.43 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (MXCT)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $7.47M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.1 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (MXCT)
| Total Revenue | $31.05M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -14.50% |
| Gross Margin | +79.23% |
| Operating Margin | -140.72% |
| Profit Margin | -114.77% |
| ROE | -20.39% |
| Debt / Equity | 0.11 |
| Current Ratio | 12.26 |
| Total Cash | $105.69M |
| Total Debt | $17.25M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$36.18M (-109.5% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (MXCT)
Nexqual rates MaxCyte, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -15% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $106M cash vs $17M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$36M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -20%, ROA -10.6% |
Ownership (MXCT)
| Insider Ownership | +1.84% |
|---|---|
| Institutional Ownership | +61.73% |
| Shares Outstanding | 103.21M |
| Float | 93.72M |
| Short % of Float | +1.07% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (MXCT)
MaxCyte, Inc. is led by Maher Masoud (age 49), President, CEO & Executive Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Executive Director | Maher Masoud (age 49) |
|---|---|
| Chief Financial Officer | Parmeet Ahuja (age 56) |
| Senior Vice President of Global Sales | Ana-Paula Martins Fernandes |
| Senior Vice President of Human Resources | Jill Mayer |
Major Backers & Investors (MXCT)
Notable institutional backers of MaxCyte, Inc. include Capricorn Fund Managers Ltd, Vitruvian Partners, LLP, Morgan Stanley, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capricorn Fund Managers Ltd | 7.95% |
| Vitruvian Partners, LLP | 4.89% |
| Morgan Stanley | 3.92% |
| Mudita Advisors LLP | 3.27% |
| Brooklands Fund Management Ltd | 2.76% |
| BNP Paribas Asset Management Holding S.A. | 2.69% |
| Cadian Capital Management, LP | 2.13% |
| Peapod Lane Capital LLC | 2.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.49% |
| BlackRock | 2.97% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt